ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Insider James Kihara Sells 4,073 Shares

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) insider James Kihara sold 4,073 shares of ACADIA Pharmaceuticals stock in a transaction that occurred on Tuesday, November 19th. The shares were sold at an average price of $16.81, for a total transaction of $68,467.13. Following the sale, the insider now owns 19,863 shares of the company’s stock, valued at approximately $333,897.03. The trade was a 17.02 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

ACADIA Pharmaceuticals Stock Performance

Shares of ACAD opened at $16.21 on Wednesday. The stock has a market capitalization of $2.70 billion, a PE ratio of 20.78 and a beta of 0.38. ACADIA Pharmaceuticals Inc. has a 1 year low of $14.15 and a 1 year high of $32.59. The company’s 50-day simple moving average is $15.60 and its 200-day simple moving average is $15.99.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its quarterly earnings results on Wednesday, November 6th. The biopharmaceutical company reported $0.20 EPS for the quarter, topping the consensus estimate of $0.14 by $0.06. ACADIA Pharmaceuticals had a net margin of 13.83% and a return on equity of 25.83%. The company had revenue of $250.40 million during the quarter, compared to analysts’ expectations of $248.83 million. During the same quarter in the previous year, the business posted ($0.40) EPS. The firm’s revenue was up 18.3% on a year-over-year basis. On average, sell-side analysts predict that ACADIA Pharmaceuticals Inc. will post 0.72 earnings per share for the current year.

Wall Street Analysts Forecast Growth

ACAD has been the subject of several research reports. Raymond James restated a “market perform” rating on shares of ACADIA Pharmaceuticals in a research note on Thursday, October 10th. UBS Group cut their price target on shares of ACADIA Pharmaceuticals from $25.00 to $23.00 and set a “buy” rating for the company in a report on Thursday, August 8th. HC Wainwright reaffirmed a “buy” rating and set a $27.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Needham & Company LLC reaffirmed a “buy” rating and set a $28.00 target price on shares of ACADIA Pharmaceuticals in a report on Thursday, November 7th. Finally, Royal Bank of Canada dropped their price objective on shares of ACADIA Pharmaceuticals from $29.00 to $26.00 and set an “outperform” rating for the company in a report on Wednesday, August 7th. Six equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $25.56.

Institutional Trading of ACADIA Pharmaceuticals

Several institutional investors have recently modified their holdings of ACAD. Park Place Capital Corp purchased a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $25,000. Values First Advisors Inc. purchased a new stake in shares of ACADIA Pharmaceuticals during the 3rd quarter worth approximately $27,000. Covestor Ltd lifted its position in shares of ACADIA Pharmaceuticals by 70.5% during the 1st quarter. Covestor Ltd now owns 2,032 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 840 shares during the last quarter. Quest Partners LLC lifted its position in shares of ACADIA Pharmaceuticals by 42.3% during the 3rd quarter. Quest Partners LLC now owns 3,520 shares of the biopharmaceutical company’s stock worth $54,000 after buying an additional 1,047 shares during the last quarter. Finally, Stonepine Capital Management LLC purchased a new stake in shares of ACADIA Pharmaceuticals during the 2nd quarter worth approximately $81,000. Hedge funds and other institutional investors own 96.71% of the company’s stock.

ACADIA Pharmaceuticals Company Profile

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.